NCT00807235 - Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

August 31, 2005

Study Completion Date

September 30, 2005

Conditions

Respiratory Distress Syndrome

Interventions

DRUG

Aerosolized lucinactant

Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 3 hours.

DRUG

Aerosolized lucinactant

Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 1 hour.

Trial Locations (1)

92103

University of California, San Diego Medical Center - Hillcrest, San Diego